Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Has Consensus Target Price of $44.25

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been given an average rating of “Moderate Buy” by the eleven brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and ten have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $44.25.

Several equities research analysts have recently commented on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Stoke Therapeutics in a report on Friday, August 7th. JPMorgan Chase & Co. began coverage on shares of Stoke Therapeutics in a research note on Friday, August 21st. They set an “overweight” rating and a $40.00 price objective on the stock. Chardan Capital reissued a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Wedbush boosted their price objective on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Finally, The Goldman Sachs Group restated a “buy” rating on shares of Stoke Therapeutics in a report on Thursday, September 10th.

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock opened at $24.80 on Wednesday. The stock’s fifty day moving average price is $30.22 and its 200-day moving average price is $31.51. The firm has a market cap of $1.60 billion, a P/E ratio of -7.43 and a beta of 1.23. Stoke Therapeutics has a 12 month low of $20.32 and a 12 month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%.The business had revenue of $9.32 million during the quarter, compared to analysts’ expectations of $4.89 million. Analysts forecast that Stoke Therapeutics will post -3.52 earnings per share for the current year.

Insider Activity

In other news, Director Edward Kaye sold 12,567 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $402,521.01. Following the completion of the transaction, the director directly owned 124,557 shares of the company’s stock, valued at approximately $3,989,560.71. The trade was a 9.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Jonathan Allan sold 2,861 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $91,637.83. Following the sale, the general counsel owned 21,225 shares of the company’s stock, valued at $679,836.75. This trade represents a 11.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 32,916 shares of company stock worth $1,025,302. 9.60% of the stock is currently owned by company insiders.

Institutional Trading of Stoke Therapeutics

Hedge funds have recently modified their holdings of the company. Tidal Investments LLC raised its stake in shares of Stoke Therapeutics by 16.1% during the 2nd quarter. Tidal Investments LLC now owns 9,917 shares of the company’s stock worth $324,000 after acquiring an additional 1,377 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Stoke Therapeutics in the second quarter valued at approximately $959,000. Corient Private Wealth LP acquired a new stake in Stoke Therapeutics in the second quarter valued at approximately $1,009,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Stoke Therapeutics in the second quarter valued at approximately $443,000. Finally, Seven Fleet Capital Management LP purchased a new position in Stoke Therapeutics in the second quarter worth $255,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc is a biotechnology company focused on developing RNA-based medicines for severe genetic diseases. The company’s approach is designed to increase the production of functional proteins by selectively targeting RNA splicing, a process that helps determine how genetic information is translated into proteins.

Stoke’s technology is based on its TANGO platform, which uses antisense oligonucleotides to promote the inclusion of productive genetic sequences in messenger RNA.